All Stories

  1. Towards a subunit vaccine from a Shigella flexneri ΔtolR mutant
  2. Maternal Vaccination. Immunization of Sows during Pregnancy against ETEC Infections
  3. Oral immunotherapy using polymeric nanoparticles loaded with peanut proteins in a murine model of fatal anaphylaxis
  4. Adjuvants for allergy immunotherapeutics
  5. Chitosan/sulfated locust bean gum nanoparticles: In vitro and in vivo evaluation towards an application in oral immunization
  6. Topical immunization using a nanoemulsion containing bacterial membrane antigens
  7. Improved effect of amikacin-loaded Poly (D, L-lactide-co-glycolide) (PLGA) nanoparticles against Planktonic and biofilm cells of Pseudomonas aeruginosa
  8. Zein nanoparticles for oral delivery of quercetin: Pharmacokinetic studies and preventive anti-inflammatory effects in a mouse model of endotoxemia
  9. New pharmaceutical approaches for the treatment of food allergies
  10. Amikacin loaded PLGA nanoparticles against Pseudomonas aeruginosa
  11. Interactions of poly (anhydride) nanoparticles with macrophages in light of their vaccine adjuvant properties
  12. Mimicking microbial strategies for the design of mucus-permeating nanoparticles for oral immunization
  13. Nucleic acid vaccination strategies against infectious diseases
  14. Zein-Based Nanoparticles Improve the Oral Bioavailability of Resveratrol and Its Anti-inflammatory Effects in a Mouse Model of Endotoxic Shock
  15. Nanoparticles as Adjuvants for Vaccination
  16. Development of a Bacterial Nanoparticle Vaccine
  17. Nanoparticle based-immunotherapy against allergy
  18. Immunogenicity of Peanut Proteins Containing Poly(Anhydride) Nanoparticles
  19. Vaccine Delivery Systems for Veterinary Immunization
  20. Antigen Delivery Systems as Oral Adjuvants
  21. Nanoparticle-based vaccine for mucosal protection against Shigella flexneri in mice
  22. Gentamicin-Loaded Nanoparticles Are Effective against Brucella melitensis
  23. Towards a non-living vaccine against Shigella flexneri: From the inactivation procedure to protection studies
  24. Radiomarcaje y estudios de biodistribución de nanopartículas poliméricas como adyuvantes para la vacunación oftálmica frente a la brucelosis
  25. Recent progress towards development of aShigellavaccine
  26. Development of poly(anhydride) nanoparticles loaded with peanut proteins: The influence of preparation method on the immunogenic properties
  27. Conjunctival vaccination against Brucella ovis in mice with mannosylated nanoparticles
  28. Cellular pharmacokinetics and intracellular activity against Listeria monocytogenes and Staphylococcus aureus of chemically modified and nanoencapsulated gentamicin
  29. Chapter 2.3. Nanostructures for Oral Vaccine Delivery
  30. Acellular vaccines for ovine brucellosis: a safer alternative against a worldwide disease
  31. Nanoparticulate Adjuvants and Delivery Systems for Allergen Immunotherapy
  32. Mucosal immunization with Shigella flexneri outer membrane vesicles induced protection in mice
  33. Poly(methyl vinyl ether-co-maleic anhydride) nanoparticles as innate immune system activators
  34. Nanomedicine: Novel approaches in human and veterinary therapeutics
  35. Novel bioactive hydrophobic gentamicin carriers for the treatment of intracellular bacterial infections
  36. Ara H 9 Is The Main Allergen In Peanut Allergic Patients In The Mediterranean Area Regardless The Symptom Severity
  37. High Loading of Gentamicin in Bioadhesive PVM/MA Nanostructured Microparticles Using Compressed Carbon-Dioxide
  38. Poly(Anhydride) Nanoparticles Act as Active Th1 Adjuvants through Toll-Like Receptor Exploitation
  39. Influence of dextran on the bioadhesive properties of poly(anhydride) nanoparticles
  40. Evaluation of particulate acellular vaccines against Brucella ovis infection in rams
  41. Differences In The Immunologic Response To Peanut Allergen Depending Upon The Route, Lipid Content And Peanut Roasting In An Animal Model
  42. Drug delivery systems for potential treatment of intracellular bacterial infections
  43. Biofilm formation by Salmonella in food processing environments
  44. New adjuvants: from empiricism to science
  45. A novel nanoparticulate adjuvant for immunotherapy with Lolium perenne
  46. Immunoadjuvant capacity of flagellin and mannosamine-coated poly(anhydride) nanoparticles in oral vaccination
  47. Design and influence of γ-irradiation on the biopharmaceutical properties of nanoparticles containing an antigenic complex from Brucella ovis
  48. Co-Delivery of Ovalbumin and CpG Motifs into Microparticles Protected Sensitized Mice from Anaphylaxis
  49. Biofilm formation by Salmonella in food processing environments
  50. Allergen immunotherapy with nanoparticles containing lipopolysaccharide from Brucella ovis
  51. Stability of Poly(ε-caprolactone) Microparticles Containing Brucella ovis Antigens as a Vaccine Delivery System Against Brucellosis
  52. Co-encapsulation of an antigen and CpG oligonucleotides into PLGA microparticles by TROMS technology
  53. Evaluation of Bioadhesive Capacity and Immunoadjuvant Properties of Vitamin B12-Gantrez Nanoparticles
  54. Mannose-targeted systems for the delivery of therapeutics
  55. Bioadhesive capacity and immunoadjuvant properties of thiamine-coated nanoparticles
  56. Biodegradable gentamicin delivery systems for parenteral use for the treatment of intracellular bacterial infections
  57. Gantrez® AN nanoparticles as an adjuvant for oral immunotherapy with allergens
  58. Protective immunity of biodegradable nanoparticle-based vaccine against an experimental challenge with Salmonella Enteritidis in mice
  59. Nanoparticles as Adjuvant-Vectors for Vaccination
  60. Intradermal immunization with ovalbumin-loaded poly-?-caprolactone microparticles conferred protection in ovalbumin-sensitized allergic mice
  61. Gamma Interferon Loaded onto Albumin Nanoparticles: In Vitro and In Vivo Activities against Brucella abortus
  62. Poly(d,l-Lactide-Coglycolide) Particles Containing Gentamicin: Pharmacokinetics and Pharmacodynamics in Brucella melitensis- Infected Mice
  63. Encapsulation of antigenic extracts of Salmonella enterica serovar
  64. Chemical and Biological Factors in the Control of Brucella and Brucellosis
  65. Bioadhesive Mannosylated Nanoparticles for Oral Drug Delivery
  66. Development of a Novel Vaccine Delivery System Based on Gantrez Nanoparticles
  67. Nanocarriers with Gentamicin to Treat Intracellular Pathogens
  68. Intracellular killing of Brucella melitensis in human macrophages with microsphere-encapsulated gentamicin
  69. Determination of gentamicin in different matrices by a new sensitive high-performance liquid chromatography-mass spectrometric method
  70. Experiments on a sub-unit vaccine encapsulated in microparticles and its efficacy against Brucella melitensis in mice
  71. Brucella outer membrane complex-loaded microparticles as a vaccine against Brucella ovis in rams
  72. Optimization of the entrapment of bacterial cell envelope extracts into microparticles for vaccine delivery
  73. Biodegradable micro- and nanoparticles as long-term delivery vehicles for gentamicin
  74. BapA, a large secreted protein required for biofilm formation and host colonization of Salmonella enterica serovar Enteritidis
  75. Salmonella-like bioadhesive nanoparticles
  76. Gentamicin-loaded microspheres for treatment of experimental Brucella abortus infection in mice
  77. Bioadhesive properties of pegylated nanoparticles
  78. Protective ability of subcellular extracts from Salmonella Enteritidis and from a rough isogenic mutant against salmonellosis in mice
  79. Gantrez® AN nanoparticles do not alter allergenicity of Lollium extract
  80. Role of the GGDEF protein family in Salmonella cellulose biosynthesis and biofilm formation
  81. Humoral immune response in hens naturally infected withSalmonellaEnteritidis against outer membrane proteins and other surface structural antigens
  82. Gentamicin-loaded microspheres for reducing the intracellular Brucella abortus load in infected monocytes
  83. New Therapeutic Approaches for the Treatment of Brucella Infections: Gentamicin Entrapment into Drug Delivery Systems
  84. Influence of the co-encapsulation of different excipients on the properties of polyester microparticle-based vaccine against brucellosis
  85. Polymeric carriers for amphotericin B: in vitro activity, toxicity and therapeutic efficacy against systemic candidiasis in neutropenic mice
  86. Modulation of the cellular immune response after oral or subcutaneous immunization with microparticles containing Brucella ovis antigens
  87. Development of microparticles prepared by spray-drying as a vaccine delivery system against brucellosis
  88. In vitro evaluation of gentamicin released from microparticles
  89. In vitro phagocytosis and monocyte-macrophage activation with poly(lactide) and poly(lactide-co-glycolide) microspheres
  90. Genetic analysis ofSalmonella enteritidisbiofilm formation: critical role of cellulose
  91. Polyester Microparticles as a Vaccine Delivery System for Brucellosis: Influence of the Polymer on Release, Phagocytosis and Toxicity
  92. Promotion of platelet aggregation by sera from brucellosis patients with antiphosphatidylcholine antibodies
  93. A Brucella ovis antigenic complex bearing poly-ε-caprolactone microparticles confer protection against experimental brucellosis in mice
  94. Virulent strains of Salmonella enteritidis disrupt the epithelial barrier of Caco-2 and HEp-2 cells
  95. The relationship between glycogen synthesis, biofilm formation and virulence in Salmonella enteritidis
  96. The relationship between glycogen synthesis, biofilm formation and virulence in Salmonella enteritidis
  97. Enzyme-linked immunosorbent assay with a Salmonella enteritidis antigen for differentiating infected from vaccinated poultry
  98. Gentamicin encapsulation in PLA/PLGA microspheres in view of treating Brucella infections
  99. Anti-Phosphatidylcholine Antibodies in Patients with Brucellosis
  100. Poly(ε-caprolacton) nanospheres as an alternative way to reduce amphotericin B toxicity
  101. Protective Effect of Liposomal Gentamicin against Systemic Acute Murine Brucellosis
  102. Inadequate Azithromycin Activity againstBrucella melitensisin Mice with Acute or Chronic Infections
  103. Antibiotic treatment induces an increase of the specific antibody levels in Brucella melitensis infected mice
  104. Antibiotic treatment induces an increase of the specific antibody levels in Brucella melitensis infected mice
  105. Protective effect of Brucella outer membrane complex-bearing liposomes against experimental murine brucellosis
  106. Protective effect of Brucella outer membrane complex-bearing liposomes against experimental murine brucellosis
  107. Comparative activity of azithromycin and doxycycline against Brucella spp. infection in mice
  108. Brucella group 3 outer membrane proteins contain a heat-modifiable protein
  109. Brucella group 3 outer membrane proteins contain a heat-modifiable protein
  110. Evaluation of whole cell and subcellular vaccines against Brucella ovis in rams
  111. An ELISA with Brucella lipopolysaccharide antigen for the diagnosis of B. melitensis infection in sheep and for the evaluation of serological responses following subcutaneous or conjunctival B. melitensis strain Rev 1 vaccination
  112. Comparison of three serological tests for Brucella ovis infection of rams using different antigenic extracts
  113. Properties of the outer membrane of Brucella